{"id":"129-xe","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":{"setId":"70e33fe3-c722-439b-b3db-c2a22f229c8a","title":"XENOVIEW (XENON XE 129 HYPERPOLARIZED) GAS [POLAREAN, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Xenon-129 is a noble gas that can be hyperpolarized to enhance its MRI signal, allowing direct visualization of ventilation patterns and alveolar gas distribution in the lungs. When inhaled, it distributes throughout the airways and alveoli, providing functional imaging of pulmonary ventilation without ionizing radiation. This enables assessment of regional lung function in both healthy and diseased states.","oneSentence":"129-Xe is a hyperpolarized xenon-129 gas used as a contrast agent for magnetic resonance imaging (MRI) to visualize lung ventilation and gas exchange.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:41:40.704Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary ventilation imaging via MRI"},{"name":"Assessment of regional lung function in cystic fibrosis, asthma, and chronic obstructive pulmonary disease"}]},"trialDetails":[{"nctId":"NCT02272049","phase":"PHASE1, PHASE2","title":"Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-12","conditions":"Respiratory Disorders","enrollment":300},{"nctId":"NCT04035629","phase":"PHASE1","title":"129Xe MRI in Pediatric Population With BPD","status":"WITHDRAWN","sponsor":"Xemed LLC","startDate":"2026-08-01","conditions":"Bronchopulmonary Dysplasia","enrollment":""},{"nctId":"NCT04995562","phase":"PHASE4","title":"Use of Hyperpolarized 129Xe MR Lung Imaging in Infants","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2020-05-06","conditions":"Lungs; Developmental Disorder","enrollment":12},{"nctId":"NCT04991389","phase":"PHASE4","title":"Improving Outcomes in Pediatric Obstructive Sleep Apnea With Computational Fluid Dynamics","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2019-08-15","conditions":"Obstructive Sleep Apnea","enrollment":120},{"nctId":"NCT05914506","phase":"","title":"Hyperpolarized 129-Xenon MRI in Fibrosing Interstitial Lung Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Aarhus","startDate":"2023-10-05","conditions":"Progressive Fibrosing Interstitial Lung Disease","enrollment":30},{"nctId":"NCT07192016","phase":"PHASE4","title":"129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2026-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":60},{"nctId":"NCT02316379","phase":"PHASE1, PHASE2","title":"Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2015-02","conditions":"Respiratory Disorders","enrollment":100},{"nctId":"NCT03733535","phase":"NA","title":"Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dr. Grace Parraga","startDate":"2022-03-01","conditions":"Asthma; Eosinophilic","enrollment":29},{"nctId":"NCT06271408","phase":"PHASE1","title":"Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation Imaging","status":"UNKNOWN","sponsor":"Polarean, Inc.","startDate":"2024-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":6},{"nctId":"NCT02976935","phase":"","title":"Functional MR Lung Imaging Using Hyperpolarised 129Xe","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2014-02","conditions":"COPD, IPF","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":634,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"129-Xe","genericName":"129-Xe","companyName":"Children's Hospital Medical Center, Cincinnati","companyId":"children-s-hospital-medical-center-cincinnati","modality":"Small molecule","firstApprovalDate":"","aiSummary":"129-Xe is a hyperpolarized xenon-129 gas used as a contrast agent for magnetic resonance imaging (MRI) to visualize lung ventilation and gas exchange. Used for Lung ventilation and gas exchange imaging in patients with chronic obstructive pulmonary disease (COPD), Assessment of regional lung function in asthma and other respiratory conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}